Related Experiment Video

Updated: Jul 12, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the

M S Freedman1, G S Francis, E A C M Sanders

  • 1Ottawa Hospital - General Campus, Ottawa, Ontario, Canada. mfreedman@ottawahospital.on.ca

Multiple Sclerosis (Houndmills, Basingstoke, England)
|March 1, 2005
PubMed
Abstract

Insights

Once weekly interferon beta-1a showed MRI benefits but no significant relapse reduction in multiple sclerosis patients over three years. This dosing regimen lacks meaningful clinical benefit compared to other interferon beta-1a treatments.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • The Once Weekly Interferon beta-1a for Multiple Sclerosis (OWIMS) study initially showed modest MRI benefits but no relapse reduction with once-weekly interferon (IFN) beta-1a.
  • An extension study aimed to assess the long-term efficacy and safety of this dosing regimen in relapsing-remitting multiple sclerosis (RRMS).

Purpose of the Study:

  • To evaluate the longer-term efficacy and safety of once-weekly interferon beta-1a in RRMS patients.
  • To assess magnetic resonance imaging (MRI) lesion activity and relapse rates over an extended treatment period.

Main Methods:

  • Patients initially on placebo were rerandomized to receive either 22 or 44 mcg of IFN beta-1a once weekly for two additional 48-week periods.
  • The primary outcome was MRI lesion activity, with relapse rates and other MRI measures as secondary outcomes.

Main Results:

  • After three years, no significant differences in median T2 lesion counts were observed between the 44 mcg, 22 mcg, and placebo groups.
  • Annualized relapse rates were similar across all groups, with the lowest rate in the 44 mcg group (0.77) but not statistically significant.
  • While neutralizing antibodies did not impact relapse rates, MRI active lesions increased in antibody-positive patients on 44 mcg compared to antibody-negative patients.

Conclusions:

  • Once weekly interferon beta-1a, particularly at 44 mcg, demonstrated a significant MRI effect but not a significant relapse effect compared to placebo in RRMS.
  • No significant dose-dependent effect was observed.
  • The study concluded that once-weekly dosing of interferon beta-1a does not provide meaningful clinical benefit in RRMS, unlike three-times-weekly subcutaneous administration.

More Related Videos

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies10:47

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies

Published on: October 27, 2016

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Related Concept Videos

Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...